• ABOUT US
  • OUR TEAM
    • BOARD AND MANAGEMENT
    • PORTFOLIO COMPANY CEO’S
  • PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
  • CONTACT US
    • CAREERS
  • GENERAL MEETING 2020
No announcement available or all announcement expired.
  • ABOUT US
  • OUR TEAM
    • BOARD AND MANAGEMENT
    • PORTFOLIO COMPANY CEO’S
  • PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
  • CONTACT US
    • CAREERS
  • GENERAL MEETING 2020

Dr. Bedu-Addo to Chair the Therapeutics/Cancer Immunotherapies Session and Present Phase I/IIA Results

Sep 19, 2016
-
PDS Biotechnology
Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
Wanda Technology Selected by 24Hr HomeCare
NEXT POST →
Glycotest strengthens IP portfolio
News
  • ProAxsis Limited appoints DiaPharma as distributor to key North America region
  • PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine
  • PDS Biotech launch Merck Trials
  • PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101
  • NetScientific acquires 100% control of portfolio company ProAxsis Limited
Investors
  • RNS Announcements
  • Financial Results
  • Financial Calendar
  • Investment Strategy
  • Corporate Governance
  • News
  • Other Materials
Categories
  • EMV
  • G -Tech Medical
  • Glycotest
  • Media
  • News
  • PDS Biotechnology
  • ProAxsis
  • RNS Announcements
Archives
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • February 2014
  • September 2013

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS Announcements
  • Financial Results
  • Financial Calendar
  • Investment Strategy
  • Corporate Governance
  • News
  • Other Materials
copyright
Terms of Use
Dr. Bedu-Addo to Chair the Therapeutics/Cancer Immunotherapies Session and Present Phase I/IIA Results - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.